Neurontin was approved by the Food and Drug Administration (FDA) in 1994 for use as an adjunctive medication to control partial
seizures. The drug's sponsor, Parke-Davis (now owned by Pfizer), then conducted a phase 4 uncontrolled, unblinded, postmarketing
trial known as the Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) trial, with the stated objective of studying
efficacy, safety, tolerability, and quality of life among gabapentin users while determining optimal dosage.